Ignite Creation Date:
2024-05-06 @ 7:07 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05909618
Status:
RECRUITING
Last Update Posted:
2023-11-28
First Post:
2023-05-01
Brief Title:
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Sponsor:
Sheba Medical Center
Organization:
Sheba Medical Center
Organization Data
Organization:
Sheba Medical Center
Class:
OTHER_GOV
Study ID:
Sheba-9411-22-RS-crizanlizumab
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sheba Medical Center
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Dr Ronnie Shapira
Responsible Party Title:
MD Head onco-gynecological service Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Sheba Medical Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Prof Ronit Satchi-Fainaro Director Cancer Biology Research Center Tel Aviv University Tel Aviv Israel | UNKNOWN |